Which antihypertensive medication, chlorthalidone or amlodipine, is more effective?

Chlorthalidone is More Effective Than Amlodipine for Most Hypertensive Patients

Based on the landmark ALLHAT trial and current ACC/AHA guidelines, chlorthalidone should be preferred over amlodipine as first-line antihypertensive therapy for most patients. While both drugs effectively lower blood pressure, chlorthalidone demonstrates superior outcomes in preventing heart failure and has proven cardiovascular disease reduction in large-scale trials 1, 2.

Evidence from Direct Comparison

The ALLHAT trial—the largest head-to-head comparison of antihypertensive medications—directly compared chlorthalidone, amlodipine, and lisinopril in over 33,000 high-risk hypertensive patients 3. Key findings:

• Primary outcome (coronary heart disease death/nonfatal MI): No significant difference between chlorthalidone and amlodipine 4, 3
• Heart failure: Amlodipine showed 38% higher risk compared to chlorthalidone (RR 1.38; 95% CI 1.25-1.52; p<0.001) 4, 5
• Combined cardiovascular disease: Chlorthalidone was superior to amlodipine in preventing overall cardiovascular events 4

The heart failure difference was particularly pronounced in the first year (RR 2.22 for amlodipine vs. chlorthalidone) but persisted throughout follow-up (RR 1.22 after year 1) 5.

Guideline Recommendations

The 2017 ACC/AHA guidelines explicitly state that chlorthalidone is preferred over other thiazide-type diuretics based on its prolonged half-life and proven trial reduction of cardiovascular disease 1, 2. The 2025 updated guidelines maintain that thiazide-type diuretics, long-acting dihydropyridine calcium channel blockers (like amlodipine), and ACE inhibitors/ARBs are all acceptable first-line agents 6, 7, but the evidence base for chlorthalidone remains strongest.

Clinical Scenarios Where Each Drug May Be Preferred

Choose Chlorthalidone When:

• Most patients with uncomplicated hypertension 1, 2
• Patients at risk for heart failure (chlorthalidone reduces HF risk by 27-35% vs. amlodipine) 5, 8
• Metabolic syndrome: Despite theoretical concerns about glucose effects, chlorthalidone was "unsurpassed in reducing CVD and renal outcomes" in ALLHAT's metabolic syndrome subgroup 2
• Resistant hypertension: Chlorthalidone is specifically recommended for treatment-resistant cases 9, 10
• Cost considerations: Chlorthalidone is significantly less expensive 4

Choose Amlodipine When:

• Heart failure with reduced ejection fraction (HFrEF): Guidelines specifically state to avoid most calcium channel blockers in HFrEF, though amlodipine may be used if required 1, 2
• Patients who cannot tolerate diuretics (e.g., history of severe hypokalemia, gout on maximum uric acid-lowering therapy)
• Chronic kidney disease with contraindications to diuretics: Though recent evidence suggests chlorthalidone is effective even in stage 4 CKD 10
• Vasospastic (Prinzmetal's) angina: Amlodipine has specific efficacy for coronary vasospasm 11

Important Caveats and Monitoring

For Chlorthalidone:

• Monitor electrolytes closely: Risk of hypokalemia (8.5% in ALLHAT) and hypomagnesemia 12
• Dose appropriately: Use 12.5-25 mg daily (not higher doses that increase adverse effects without added benefit) 1, 2
• Monitor glucose and uric acid: Small increases occur (1.5-4.0 mg/dL glucose increase) but did not translate to increased CVD risk in long-term follow-up 2
• Caution in gout: Use only if patient is on uric acid-lowering therapy 1

For Amlodipine:

• Expect peripheral edema: Dose-related and more common in women; occurs in 10-30% of patients 1
• Avoid in HFrEF: Unless specifically required and other options exhausted 2
• Long half-life: Takes 7-8 days to reach steady state 11

Special Populations

Black patients: Chlorthalidone showed particular benefit over lisinopril in Black patients for stroke and combined CVD outcomes, with similar superiority over amlodipine for heart failure across all racial subgroups 13.

Diabetic patients: Despite metabolic concerns, chlorthalidone showed no disadvantage for cardiovascular or renal outcomes in diabetic patients compared to amlodipine or lisinopril 3.

Elderly patients: Both drugs are effective, though amlodipine requires dose adjustment due to decreased clearance 11. Chlorthalidone's longer half-life (40-60 hours) provides more consistent 24-hour blood pressure control 9.

Bottom Line Algorithm

1. Start with chlorthalidone 12.5-25 mg daily for most newly diagnosed hypertensive patients 1, 6
2. Switch to or add amlodipine if:
   • Heart failure with reduced ejection fraction develops
   • Intolerable electrolyte disturbances occur despite supplementation
   • Severe gout flares despite uric acid-lowering therapy
   • Vasospastic angina is present
3. Monitor at 1 month: Check blood pressure, electrolytes (K+, Mg++), glucose, uric acid, and calcium 1
4. Add second agent if needed: Combination of chlorthalidone + amlodipine is rational for stage 2 hypertension or inadequate response 6, 7

The evidence strongly favors chlorthalidone as the superior first-line choice for preventing the cardiovascular complications that matter most—particularly heart failure—while maintaining equivalent efficacy for blood pressure reduction and coronary events 4, 5, 8.